Interleukin-13 -1112 C/T Promoter Polymorphism Confers Risk for COPD: A Meta-Analysis

17Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Background: Interleukin (IL)-13, a T-helper type 2 cytokine, plays a critical role in the development of chronic obstructive pulmonary disease (COPD). This meta-analysis was performed to assess the association of IL-13 -1112 C/T promoter polymorphism with COPD susceptibility. Methods: Published case-control studies from Pubmed and China National Knowledge Infrastructure (CNKI) databases were retrieved. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated. Results: Eight case-control studies in seven articles were included in this meta-analysis. Pooled effect size showed IL-13 -1112 C/T was associated with COPD susceptibility in a codominant genetic model (TT vs CT, OR: 1.82, 95% CI: 1.14-2.92 and TT vs CC, OR: 2.02, 95% CI: 1.10-3.72), indicating individuals with TT genotype had an increased risk for COPD compared with those with CT or CC genotype. According to ethnicity, results indicated IL-13 -1112 C/T was correlated with COPD susceptibility in Arabians (TT vs CT, OR: 2.94, 95% CI: 1.03-8.42 and TT vs CC, OR: 3.05, 95% CI: 1.08-8.59). Moreover, after excluding the study without Hardy-Weinberg equilibrium, the pooled results were robust and no publication bias was found in this study. Conclusions: This meta-analysis suggests IL-13 -1112 C/T promoter polymorphism is associated with the risk of COPD in Arabians. © 2013 Chen et al.

Cite

CITATION STYLE

APA

Chen, L., Shen, Y., Liu, L., Li, X., Wang, T., & Wen, F. (2013). Interleukin-13 -1112 C/T Promoter Polymorphism Confers Risk for COPD: A Meta-Analysis. PLoS ONE, 8(7). https://doi.org/10.1371/journal.pone.0068222

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free